IRadimed Corporation (IRMD)
| Market Cap | 402.07M |
| Revenue (ttm) | 44.90M |
| Net Income (ttm) | 10.43M |
| Shares Out | 12.56M |
| EPS (ttm) | 0.83 |
| PE Ratio | 38.61 |
| Forward PE | 32.15 |
| Dividend | $1.00 (3.12%) |
| Ex-Dividend Date | Feb 16, 2022 |
| Volume | 84,390 |
| Open | 33.25 |
| Previous Close | 33.21 |
| Day's Range | 31.92 - 33.25 |
| 52-Week Range | 27.72 - 55.92 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 45.90 (+43.4%) |
| Earnings Date | Jul 29, 2022 |
About IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensor... [Read more...]
Financial Performance
In 2021, IRadimed's revenue was $41.81 million, an increase of 31.83% compared to the previous year's $31.72 million. Earnings were $9.33 million, an increase of 581.19%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for IRMD stock is "Buy." The 12-month stock price forecast is 45.9, which is an increase of 43.39% from the latest price.
News
IRADIMED Names John F. Glenn Chief Financial Officer
WINTER SPRINGS, Fla., May 26, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 2...
After Plunging 27.4% in 4 Weeks, Here's Why the Trend Might Reverse for iRadimed (IRMD)
iRadimed (IRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea...
iRadimed (IRMD) is an Incredible Growth Stock: 3 Reasons Why
iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IRadimed (IRMD) Q1 Earnings and Revenues Top Estimates
iRadimed (IRMD) delivered earnings and revenue surprises of 4.76% and 0.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IRADIMED CORPORATION Announces First Quarter 2022 Financial Results
WINTER SPRINGS, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2022. The Company...
IRADIMED CORPORATION Announces Executive Transition
WINTER SPRINGS, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today announced that Chris Scott, Chief Financial and Operating Officer, has resig...
IRADIMED CORPORATION to Hold 2022 First Quarter Financial Results Conference Call on April 29th
WINTER SPRINGS, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 first quarter financial results before the market open...
Here's Why Momentum in iRadimed (IRMD) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price St...
Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?
Here is how iRadimed (IRMD) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
IRADIMED Announces Special $1.00 Per Share Cash Dividend
WINTER SPRINGS, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on ...
Why iRadimed Shares Are Surging Today?
iRadimed Corporation IRMD reported Q4 FY21 sales of $11.87 million, up 39% Y/Y, beating the consensus of $11.63 million. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results
WINTER SPRINGS, Fla., Feb. 04, 2022 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices...
IRADIMED CORPORATION to Hold 2021 Fourth Quarter Financial Results Conference Call on February 4th
WINTER SPRINGS, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 fourth quarter financial results before the market open...
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price St...
Here's Why "Trend" Investors Would Love Betting on iRadimed (IRMD)
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price St...
3 Reasons Growth Investors Will Love iRadimed (IRMD)
iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Why Growth Investors Shouldn't Overlook iRadimed (IRMD)
iRadimed (IRMD) could produce exceptional returns because of its solid growth attributes.
IRadimed (IRMD) Q3 Earnings and Revenues Beat Estimates
iRadimed (IRMD) delivered earnings and revenue surprises of 35.29% and 4.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results
WINTER SPRINGS, Fla., Oct. 29, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices ...
IRadimed (IRMD) Reports Next Week: Wall Street Expects Earnings Growth
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRADIMED CORPORATION to Hold 2021 Third Quarter Financial Results Conference Call on October 29th
WINTER SPRINGS, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 third quarter financial results before the market opens...
IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results
WINTER SPRINGS, Fla., July 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices ...